Thank you for your interest in Medicom’s summary of the ISTH 2020 congress. So far in 2020 we have transitioned to virtual congresses as we grapple with the COVID-19 pandemic. In spite of these challenges, this year’s meeting was rich with novel science ranging from haemophilia to venous thromboembolism.
Focused sessions on anticoagulation provide novel insights for patients with cancer and atrial fibrillation as well as use during pregnancy. Finally.
Focused sessions on COVID-19 continue to elucidate the underlying biology of this condition including associated inflammation and coagulopathy. Early data evaluating risk of thrombosis during and after hospitalization as well as the role of anticoagulation underscores the complexity of optimal treatment in this growing pandemic.
We hope you find these summaries balanced, insightful and interesting. Most of all, we hope you are safe and healthy, and we wish you the best during these challenging times.
Sincerely,
Marc Bonaca
Biography
Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research.
Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. After completion of his training he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group.
Dr Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. His key areas of interest include patients with peripheral artery disease, polyvascular disease and diabetes with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications and major adverse cardiovascular events.
Conflict of Interest Statement:
Grant support to BWH from AstraZeneca, MedImmune, Merck, PfizerGrant support to CPC from Amgen, AstraZeneca, Bayer, Janssen, NovoNordisk, Sanofi
Posted on
Previous Article
« Surgical bleeding risk most important determinant of bleeding outcomes Next Article
Eosinophil count tied to immunotherapy’s efficacy, adverse effects in lung cancer »
« Surgical bleeding risk most important determinant of bleeding outcomes Next Article
Eosinophil count tied to immunotherapy’s efficacy, adverse effects in lung cancer »
Table of Contents: ISTH 2020
Featured articles
Haemophilia and Rare Bleeding Disorders
Novel gene therapy leads to normal FIX activity levels in severe haemophilia B
Haemophilia gene therapy: progress and obstacles
Recombinant factor VIII safe and effective in PUPs A-LONG study
What’s New in Anticoagulation
Finding the sweet spot of anticoagulation in AF patients with ACS
Lower embryopathy risk with DOAC versus VKA during pregnancy
Higher thrombotic risk in NSCLC patient with ALK rearrangement
COVID-19 and Thrombosis
Crosstalk between inflammation and coagulation in severe COVID-19 infections
COVID-19 associated with higher VTE rates relative to influenza
Therapeutic anticoagulation not associated with lower mortality rates in COVID-19 ICU patients
COVID-19 not associated with heightened VTE risk after discharge
What’s New in Venous Thromboembolism
Residual pulmonary obstruction may predict risk of VTE recurrence
Less diagnostic delay in CTEPH diagnosis with novel algorithm
Risk of checkpoint inhibitor-associated thromboembolic events important for cancer prognosis
Pearls of the Posters
Surgical bleeding risk most important determinant of bleeding outcomes
Similar bleeding rates in patients with VTE and AF treated with DOACs
Physical rehabilitation improves health outcomes after pulmonary embolism
Guidelines adherence reduces bleeding risk after surgery and childbirth for VWD patients
Factor V Leiden mutation linked to atrial fibrillation
Increased rates of arterial thromboembolism in cancer patients
Related Articles
September 8, 2020
COVID-19 not associated with heightened VTE risk after discharge
September 8, 2020
Less diagnostic delay in CTEPH diagnosis with novel algorithm
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com